Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Probiotic bacteria

A technology of probiotics and strains, applied in the field of probiotics

Active Publication Date: 2015-04-29
SKINBIOTIX LTD
View PDF18 Cites 14 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

However, genetic loss of claudin 1 is known to be lethal in mice (63)

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Probiotic bacteria
  • Probiotic bacteria
  • Probiotic bacteria

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0187] Example 1: Materials and methods

[0188] bacterial growth

[0189] Probiotics were tested in Wilkins-Dahlgren (Wilkins-Dahlgren) at 37°C in Mark 3 (Mark 3) anaerobic workstation (Whitley Scientific, Shipley, UK) (Don Whitley Scientific, Shipley, UK). Chalgren) broth (WCB) (tryptone) was routinely grown to stationary phase. Staphylococcus aureus was grown aerobically at 37°C in nutrient broth (tryptone). Adjust the culture density spectrophotometrically to contain the desired number of bacteria. For experiments using keratinocytes, bacteria were washed twice in 0.85% NaCl solution, centrifuged and reconstituted in keratinocytes. Selective agar was used in some experiments. Mannitol salts agar-MSA (tryptone) or Man-Rogosa-Sharpe agar (MRS) for Staphylococcus aureus or Lactobacillus respectively. For experiments using heat-killed bacteria, L. reuteri was centrifuged and resuspended in 0.4% glucose and heat-inactivated by placing in a hot water bath at 85 °C for 4...

Embodiment 2

[0205] Staphylococcus aureus induces cell death in primary human keratinocytes

[0206] We initially demonstrated the effect of S. aureus on keratinocyte survival by performing a trypan blue exclusion test by incubating NHEK with S. aureus at different doses. The concentration of Staphylococcus aureus was 10 5 cfu / mL, only 49.4% of keratinocytes were alive after 24 hours of infection ( figure 1 ). The number of surviving keratinocytes was reduced in a dose-dependent manner, so that the concentration of Staphylococcus aureus at 10 8 At cfu / mL, only 3.3% of keratinocytes were viable ( figure 1 ).

[0207] about 10 6 This microorganism is likely to be found, for example, in physiologically relevant concentrations in skin wound infections (7). At this concentration, 30.5% of keratinocytes were viable 24 hours after infection. This concentration was used for the adhesion test.

[0208] Lactobacillus reuteri protects keratinocytes from Staphylococcus aureus-induced cell de...

Embodiment 3

[0234] As mentioned above, we demonstrated that L. reuteri is able to partially protect primary human keratinocytes from skin pathogens such as S. aureus. In this study, we have assessed the effect of a second probiotic, Lactobacillus rhamnosus GG as well as Lactobacillus rhamnosus GG, as well as Lactobacillus and bacterium Composition of lysates. Lactobacillus rhamnosus GG was isolated from human feces (see US Patent 4839281 and US Patent 5032399) and deposited under number ATCC 53103.

[0235] Lactobacillus reuteri protects keratinocytes from Staphylococcus aureus-induced cell death

[0236] In the presence or absence of L. rhamnosus GG, L. reuteri alone or in combination (all at 10 8 / mL), normal human primary keratinocytes (KC) were exposed to Staphylococcus aureus (10 6 / mL). The survival of KCs was measured after 24 h using the trypan blue exclusion assay.

[0237]When KCs were treated with only S. aureus, only 39% of KCs were still alive 24 hours after infection (p...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention provides probiotic bacteria and lysates thereof for use in methods of medical and cosmetic treatment. Use in the treatment of infections, including skin infections and methods involving regeneration or repair of the skin barrier are contemplated.

Description

technical field [0001] The present invention relates to probiotics and in particular, but of course not excluded, to the medical and cosmetic applications of probiotics and lysates thereof. Background technique [0002] Human survival is closely related to a variety of microorganisms. Colonization in the gut is by far the greatest and gut microbes have been shown to have multiple roles in normal physiology including nutrient sequestration (3) and the development of normal immune responses (22). [0003] The normal gut microbiome is full of so-called probiotics. Digestion of these probiotics has been shown to prevent or treat gastrointestinal disorders such as antibiotic-associated diarrhea (47) and inflammatory bowel disease (42). The mechanisms underlying these effects are largely unknown. However, studies have shown that probiotics are able to inhibit intestinal colonization by pathogens. In vitro studies have shown that probiotics inhibit pathogens using multiple mech...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(China)
IPC IPC(8): A61K35/741A61K35/747A61K8/99A61P31/04A61P17/00A01N63/20A61K35/744
CPCA61K8/99A61K9/0014A61K35/745A61K35/747A61Q19/00C12N1/20A61K2800/10A61K2300/00A61Q19/08A61P17/00A61P17/02A61P17/06A61P17/10A61P31/00A61P31/04A61P31/10A01N63/20A61K2035/115A61Q17/005A61K35/744A61K35/742A61K2800/70
Inventor 凯瑟琳·奥尼尔安德鲁·麦克贝恩
Owner SKINBIOTIX LTD
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com